New Yale research points to a more personalized approach to cancer care.
The study found that a post lung cancer treatment blood test, a molecular residual disease (MRD) detector, “could inform clinical intervention, including whether to restart or intensify treatment.”
According to a Yale release, the test has its advantages even years after lung cancer patients finish their treatment. By distinguishing patients who might need to undergo more treatment, the test could improve quality of life. Additionally, “MRD could also identify patients with low risk of recurrence, possibly sparing them from further treatment and any associated drug toxicities as a result.”
The research is published in Nature Medicine.
